舒芬太尼用于急诊科及院前成人急性疼痛管理的系统评价
该系统评价按PRISMA指南检索Medline、Embase、Cochrane CENTRAL和CINAHL(至2022年2月1日)及灰色文献,纳入成人急性疼痛使用舒芬太尼的随机对照试验。共4项研究(3项急诊科、1项院前)467例参与者,因异质性未做Meta分析。鼻内舒芬太尼30分钟镇痛优于安慰剂(差异20.8%,95%CI 4.0-36.2%,p=0.01);鼻内(两项研究)和静脉(一项研究)舒芬太尼与静脉吗啡相当。轻度不良事件常见,舒芬太尼组轻度镇静倾向更高,无需要高级干预的严重不良事件。作者认为鼻内制剂可能提供一种替代的快速非肠道给药途径,但综述总体样本量小,需更大规模研究确认安全性。
要点
- 鼻内舒芬太尼30分钟镇痛优于安慰剂:差异20.8%(95%CI 4.0-36.2%,p=0.01)。
- 鼻内(两项研究)和静脉(一项研究)舒芬太尼与静脉吗啡镇痛效果相当。
- 舒芬太尼组轻度镇静倾向高于吗啡,但无需要高级干预的严重不良事件。
- 作者认为鼻内制剂可能为急诊科和院前患者提供替代的快速非肠道给药途径。
- 综述总体样本量小(n=467),需更大规模研究确认安全性。
适用人群与场景
- 急诊科或院前环境中患有急性疼痛的成人患者。
处置流程与药物剂量
- 鼻内舒芬太尼可用于成人急性疼痛的快速镇痛(两项研究显示与静脉吗啡相当,一项研究显示30分钟优于安慰剂)。
- 静脉舒芬太尼可用于成人急性疼痛的快速镇痛(一项研究显示与静脉吗啡相当)。
研究设计与关键结果
- 系统评价纳入4项随机对照试验(3项急诊科、1项院前),共467例参与者;因异质性未进行Meta分析。
- 鼻内舒芬太尼30分钟镇痛优于安慰剂:差异20.8%(95%CI 4.0-36.2%,p=0.01)。
- 鼻内舒芬太尼(两项研究)和静脉舒芬太尼(一项研究)与静脉吗啡镇痛效果相当。
- 轻度不良事件常见,舒芬太尼组轻度镇静倾向高于吗啡;无需要高级干预的严重不良事件。
- 纳入研究总体质量高。
证据类型、等级与局限
- 证据类型:系统评价(按PRISMA指南进行,检索Medline、Embase、Cochrane CENTRAL、CINAHL及灰色文献至2022年2月1日)。
- 偏倚风险使用Cochrane Risk of Bias 2工具评估,纳入研究总体质量高。
- 局限:因异质性未进行Meta分析;综述总体样本量小,需更大规模研究确认安全性。
对床旁实践的改变
- 作者认为鼻内舒芬太尼可能为急诊科和院前患者提供一种替代的、快速的非肠道给药途径。
- 舒芬太尼在急诊科快速缓解急性疼痛方面与静脉吗啡相当、优于安慰剂,安全性相似,但证据样本量小。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Pain is commonly encountered in the Emergency Department (ED) and pre-hospital setting and often requires opioid analgesia. We sought to synthesize the available evidence on the effectiveness of sufentanil for acute pain relief for adult patients in the pre-hospital or ED setting.
METHODS: This systematic review was conducted in accordance with PRISMA guidelines. Medline, Embase, Cochrane CENTRAL, and CINAHL were searched from inception to February 1, 2022. The grey literature was also searched. We included randomized controlled trials of adult patients with acute pain who were treated with sufentanil. Two reviewers independently completed screening, full text review, and data extraction. Primary outcome was reduction in pain. Secondary outcomes included adverse events, need for rescue analgesia, and patient and provider satisfaction. Risk of bias was assessed using the Cochrane Risk of Bias 2 tool. A meta-analysis was not performed due to heterogeneity.
RESULTS: Of 1120 unique citations, four studies (3 ED and 1 pre-hospital) met full inclusion criteria (n = 467 participants). The overall quality of the included studies was high. Intranasal (IN) sufentanil was superior to placebo for pain relief at 30 min (difference 20.8%, 95% CI 4.0-36.2%, p = 0.01). Both IN (two studies) and IV sufentanil (one study) were comparable to IV morphine. Mild adverse events were common and there was a higher propensity for minor sedation in patients receiving sufentanil. There were no serious adverse events requiring advanced interventions.
CONCLUSION: Sufentanil was comparable to IV morphine and was superior to placebo for rapid relief of acute pain in the ED setting. The safety profile of sufentanil is similar to IV morphine in this setting, with minimal concern for serious adverse events. The intranasal formulation may provide an alternative, rapid, non-parenteral route that could benefit our unique emergency department and pre-hospital patient population. Due to the overall small sample size of this review, larger studies are required to confirm safety.
参考来源
- Hutchings C, Yadav K, Cheung WJ, et al. A systematic review of sufentanil for the management of adults with acute pain in the emergency department and pre-hospital setting. Am J Emerg Med. 2023. PMID: 37186978. doi:10.1016/j.ajem.2023.04.020
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。